3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Glioblastoma
60
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
39
Head and Neck Neoplasms
26
Gliosarcoma
26
Squamous Cell Carcinoma of Head and Neck
25
Pancreatic Neoplasms
25
Central Nervous System Neoplasms
23
Brain Neoplasms
22
Rectal Neoplasms
21
Breast Neoplasms
17
Astrocytoma
17
Sarcoma
16
Neoplasms
16
Glioma
15
Uterine Cervical Neoplasms
14
Prostatic Neoplasms
14
Esophageal Neoplasms
14
Carcinoma, Squamous Cell
11
Lymphoma, Follicular
10
Leukemia
10
Melanoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Neoplasm Metastasis
7
Myelodysplastic Syndromes
7
Lymphoma, Mantle-Cell
7
Interventions
Cyclophosphamide
7
fludarabine phosphate
6
fludarabine
5
Immunotherapy, Adoptive
3
blinatumomab
2
Cytarabine
2
Azacitidine
2
AP 1903 reagent
2
venetoclax
1
tisagenlecleucel
1
ruxolitinib
1
relugolix
1
pulrodemstat besilate
1
niraparib
1
nilotinib
1
enzalutamide
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Rituximab
1
Radiotherapy
1
NKTR-255
1
Melphalan
1
Injections
1
Imatinib Mesylate
1
GNKG168
1
Dasatinib
1
Cetuximab
1
CTL019 chimeric antigen receptor
1
CD3 Complex
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasm, Residual
×
Radiotherapy
×
Clear all
NCT03945721
2025-09-29
UNITY
Massachusetts General Hospital
Phase 1
Active not recruiting
21 enrolled